E2F2 and ovarian carcinoma: It was reported that E2F2, as an oncogene, is prominently upregulated in patients with ovarian cancer, and aberrant overexpression of E2F2 is obviously correlated with poor clinical outcomes based on multiple bioinformatics database 14.